Overview
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Glaxo WellcomeTreatments:
Ranitidine
Ranitidine bismuth citrate
Criteria
Inclusion CriteriaPatients must have:
- Asymptomatic HIV-1 infection.
- CD4 count of 400-700 cells/mm3.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Significant illness.
- Acute illness at randomization.
- Hemodialysis.
Prior Medication:
Excluded:
- Antiretroviral use within 60 days prior to study entry.